Join our Free Newsletter and unlock 50% off AltIndexFree newsletter + 50% offJoin free

Did BioNexus Gene Lab Beat Earnings?

BioNexus Gene Lab (BGLC) reported Q2 '24 revenue of $2M, with reported EPS of $0.11.

AltIndex tracks earnings alongside 25+ alternative data signals that can move ahead of the report — BioNexus Gene Lab’s job postings, web traffic, and employee business outlook. See the full BGLC stock analysis or the earnings calendar for upcoming reports.

BioNexus Gene Lab Quarterly Financial Trends ()

MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Revenue2.6M2.5M2.1M2.3M2.5M480,00023,00076,000
Gross margin12.4%12.3%16.1%16.3%14.8%-0.8%-99.5%17.0%
Operating margin-50.9%-31.7%-28.9%-27.0%-27.6%-213.3%-2,501.7%-370.8%
Net income-1.3M-350,000-620,000-620,000-710,000-1M-540,000-290,000
Net margin-51.1%-13.8%-29.2%-27.3%-27.9%-214.2%-2,379.7%-376.1%
EPS————————

BioNexus Gene Lab Earnings Trend Analysis

Over the eight quarters from Q3 '24 to Q2 '26, BioNexus Gene Lab’s quarterly revenue moved from $2.6M to $76,000. Net margin compressed from -51.1% to -376.1%, against a 17% gross margin in the most recent quarter — a read on whether revenue growth is translating into profit.

When Is BioNexus Gene Lab’s Next Earnings Date?

BioNexus Gene Lab reports earnings on a quarterly schedule. Its most recent report covered Q2 '24. For the confirmed upcoming date — and every other company reporting soon — see the BGLC earnings calendar.

Frequently Asked Questions: BioNexus Gene Lab Earnings

BioNexus Gene Lab's next earnings date has not been confirmed yet. See the earnings calendar for all upcoming reports.

BioNexus Gene Lab reported Q2 '24 EPS of $0.11 on revenue of $2M. BioNexus Gene Lab reported EPS of $0.11.

BioNexus Gene Lab reported Q2 '24 revenue of $2M.

Signals like job postings, web traffic, and employee sentiment reflect business activity in real time and can move before quarterly results are reported. AltIndex combines them with 25+ others in the BGLC AI Score.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.